Studies have shown that air pollution increases the death rates of COVID-19, and that many recovering patients show symptoms similar to asthma or COPD. Poorly balanced asthma and COPD also seem to be a risk factor for a severe coronavirus disease.
KAMU Asthma is a solution that helps patients monitor their lung condition, medication and symptoms with a clinical-grade mobile spirometer and a smartphone app. The app also includes a local forecast for weather and air quality. With KAMU, the user can see if their lung condition is deteriorating and take action, for example by adjusting their medication or avoiding going out when the air quality is low.
Data can be easily shared from the user’s smartphone to for example healthcare professionals and researchers, if the user allows it. KAMU can thus help the users feel better and more secure, save healthcare resources and provide valuable data for research purposes. Due to the coronavirus epidemic, KAMU Asthma app is now available free of charge in 18 European countries.
Healthcare is under extreme pressure during the current COVID-19 pandemic worldwide. At the same time, key risk groups with chronic respiratory conditions are not able to get quality care due to increased risk associated with visiting the care facilities and the lack of personnel resources.
A personal spirometer like KAMU Spiro is hygienic and safe for both the patient and the healthcare professionals. It’s also cost-efficient, as it reduces the need for moving between the home and the clinic, saving time and money. Read more about KAMU’s services for healthcare providers.
Both symptomatic as well as asymptomatic Covid-19 patients show various degrees of lung tissue changes. It is currently unclear what the long-term effect and recovery of these changes takes place. KAMU provides a platform for collecting patient reported outcomes in an easy and quality-controlled way. Read more about using KAMU for research purposes.